Drugs / Evorpacept
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05524545 | Nov 2022 → Jun 2025 | urinary bladder cancer, urothelial carcinoma | ALX Oncology Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04755244 | May 2021 → May 2023 | acute myeloid leukemia | ALX Oncology Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT04417517 | Oct 2020 → Jan 2025 | myelodysplastic syndrome | ALX Oncology Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03013218 | Feb 2017 → Feb 2022 | metastatic malignant neoplasm, non-Hodgkin lymphoma | ALX Oncology Inc. | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05868226 | Feb 2023 → Dec 2030 expected | HER2 positive breast carcinoma, colon adenocarcinoma, hormone receptor-positive breast cancer, metastatic malignant neoplasm +2 | QuantumLeap Healthcare Collaborative | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05025800 | Oct 2021 → Mar 2028 expected | Richter transformation, composite lymphoma, high grade B-cell lymphoma, mantle cell lymphoma +2 | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05027139 | Sep 2021 → Aug 2025 | carcinoma | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT04643002 | Jan 2021 → Sep 2027 expected | plasma cell myeloma | Sanofi | Recruiting | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT07007559 | Dec 2025 → Dec 2027 expected | breast cancer | ALX Oncology Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05787639 | Feb 2024 → Oct 2026 expected | oropharynx cancer | University of California, San Diego | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05467670 | Mar 2023 → Apr 2026 overdue | ovarian cancer | Alexander B Olawaiye, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05167409 | Jul 2022 → Oct 2024 | colorectal cancer | University of Colorado, Denver | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04675333 | May 2021 → Mar 2025 overdue | head and neck squamous cell carcinoma | ALX Oncology Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04675294 | Apr 2021 → Mar 2025 overdue | head and neck squamous cell carcinoma | ALX Oncology Inc. | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05002127 | Jan 2022 → May 2024 overdue | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | ALX Oncology Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Evorpacept | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07007559 ↗ |
| Known as | ALX148 | “Drug: Evorpacept (ALX148)” NCT05167409 ↗ |
| Known as | Lggl-alx-148 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297880 ↗ |
| Known as | Sirpa variant alx148 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297880 ↗ |
| Action | Inhibit | “a high-affinity CD47-blocking protein” PMID 34793719 ↗ Nov 2021 |
| Modality | Protein / enzyme biologic | “a novel fusion protein comprising a high-affinity CD47-SIRPα immune checkpoint inhibitor to promote tumor cell phagocytosis and inactive Fc domain to spare healthy cells” PMID 40207726 ↗ Apr 2025 |
| Route | Intravenous | “patients received intravenous evorpacept” PMID 40207726 ↗ Apr 2025 |
| Target | CD47 | “Fusion protein that blocks CD47-SIRPalpha pathway” NCT04417517 ↗ |